AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)

C. Cardone, B. Blauensteiner, V. Moreno-Viedma, M. C. Paul, G. Martini, P. P. Vitiello, D. Ciardiello, C. Borrelli, L. Poliero, P. Vitale, N. Zanaletti, V. Famiglietti, A. M. Rachiglio, D. Rizzi, E. Maiello, T. P. Latiano, N. Normanno, M. Sibilia, F. Ciardiello, E. Martinelli

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)viii30
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
Publication statusPublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Cardone, C., Blauensteiner, B., Moreno-Viedma, V., Paul, M. C., Martini, G., Vitiello, P. P., Ciardiello, D., Borrelli, C., Poliero, L., Vitale, P., Zanaletti, N., Famiglietti, V., Rachiglio, A. M., Rizzi, D., Maiello, E., Latiano, T. P., Normanno, N., Sibilia, M., Ciardiello, F., & Martinelli, E. (2018). AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii30. https://doi.org/10.1093/annonc/mdy269.094